Full Press Release Details
Named to Zhongguancun's Top 20 Most Influential Brands
December 22, 8:00 am ET
Dec. 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Alternext US: SVA), a
leading provider of vaccines in China, today announced that it was recognized as
one of Zhongguancun's Top 20 Most Influential Brands.
marks only the 30th anniversary of China's reform and market liberation program
along with the 20th anniversary of the establishment of the Zhongguancun, a
technology hub situated in Beijing that is often referred to as "China's Silicon
Valley". The Beijing municipal government recognizes the importance of advancing
the development of this technology district that consists of more than 800
companies that contribute approximately 18% of Beijing's GDP. This year, the
Beijing municipal government conducted a comprehensive study of experiences and
developments within the Zhongguancun district for the last 20 years and named
twenty leading technology companies to be the "Top 20 Most Influential Brands".
Sinovac and other leading technology companies such as Sina, Lenovo, Aigo, Sohu
and New Oriental were the recipients of this prestigious recognition. The award
ceremony was held by the Administrative Committee of the Zhongguancun Science
Park and was entitled, "Haidian Tells the World - Celebration of the 30th
Anniversary of Reform and Liberalization, Celebration of the 20th Anniversary of
the Foundation of Zhongguancun Science Park".
Weidong Yin, Chairman, President and CEO of Sinovac Biotech Ltd., commented, "We
are pleased to be named as one of the most influential brands within the
Beijing's high technology development zone. This recognition is a testament to
Sinovac's commitment to providing comprehensive marketing and sales programs
that support our brand in China. In addition, our vaccine research and
development capabilities have enabled us to successfully commercialize three
vaccines and continue to cultivate our development pipeline."
Biotech Ltd. is a China-based biopharmaceutical company that focuses on the
research, development, manufacture and commercialization of vaccines that
protect against human infectious diseases. Sinovac's commercialized vaccines
include Healive (hepatitis A), Bilive (combined hepatitis A and B), Anflu
(influenza) and Panflu(TM) (H5N1). Sinovac is currently developing Universal
Pandemic Influenza vaccine and Japanese encephalitis vaccine. Additional
information about Sinovac is available on its website, http://www.sinovac.com .
To be added to our distribution list, please email: info@sinovac.com
information, please contact:
Tel: +86-10-8289-0088
Fax: +86-10-6296-6910
Carrington/Janine McCargo
Tel: +1-646-536-7017/7033